This is a working overview of Reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-22. Anything still debated is marked as such rather than presented as settled.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Verbena officinalis in the CalPhotos photo database, University of California, Berkeley "Verbena officinalis". Calflora. Berkeley, California: The Calflora Database. "Verbena officinalis". Plants for a Future.
Macallum, A.B. & Collop (sic), J.B. (1914), "A New Substance in Nerve Cells" (read: Monday, 15 September 1913), Report of the Eighty-Third Meeting of the British Association for the Advancement of Science: Birmingham: 1913: September 10-17 (Physiology Section), pp. 673–674. Marier, Virginie & Piper, Tina (2010), "Early Twentieth-Century Canadian Medical Patent Law in Practice: James Bertram Collip and the Discovery of Emenin", University of Toronto Law Journal, Vol.60, No.3, (Summer 2010), pp. 855-892. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it".
Activision introduced the game in May 2003, but in October, Valve experienced a security breach in which hackers stole the source code for Half-Life 2. The breach required new security implementations for the engine, delaying both games; the release of Bloodlines was postponed until early 2005. Until May 2004, Troika and Activision said that the game would feature a multiplayer component and modes, including a team of vampires against a team of vampire hunters, with the ability to upgrade characters between rounds. The team was left without a producer by Activision for over a year before David Mullich was assigned to the project. With no producer oversight, Mullich found the game's design incomplete, game levels created and abandoned, and several technical issues, including problems with code for the proposed multiplayer option. The Source multiplayer code was in its infancy, increasing its development time, and the idea was abandoned. In addition to problems with the Source engine, the designers found that the game's scope exceeded their resources. Bloodlines has several playstyles, requiring different interfaces, animations, and artificial intelligence for stealth, melee combat, and first- or third-person capability. Compared to contemporary first-person shooters, with 10 to 20 animated character models, Bloodlines had over 150 characters with 3,000 unique animations, in addition to boss characters, with their movement styles. The designers underestimated the time required to develop and improve these systems.
Cmax: Maximum serum concentration that the drug achieves in the body after the drug has been administered tmax: Time to achieve maximum plasma concentration t1/2: Biological half-life In studies that were made on healthy people and people with type 2 diabetes, who were given dapagliflozin in either single ascending dose (SAD) or multiple ascending dose (MAD) showed results that confirmed a pharmacokinetic profile of the medication. With dose-dependent concentrations the half-life is about 12–13 hours, Tmax 1–2 hours and it is protein-bound, so the medication has a rapid absorption and minimal excretion by the kidney. Dapagliflozin disposition is not evidently affected by body mass index (BMI) or body weight, therefore, the pharmacokinetic findings are expected to be applicable to patients with a higher BMI. Dapagliflozin resulted in dose-dependent increases excretions in urinary glucose, up to 47g/d following single-dose administration, which can be expected from its mechanism of action. Some studies found that dapagliflozin is associated with a decrease in body weight, which is statistically superior compared to placebo or other active comparators. It is primarily associated with caloric rather than fluid loss. In contrast with other anti-hyperglycemic diabetes medications, SGLT2 inhibitors enhance, rather than suppress, gluconeogenesis and ketogenesis. Because SGLT2 inhibitors activate sirtuin 1 (and thus PGC-1α and FGF21), they are more cardioprotective than the other medications used to treat diabetes.
Unfortunately, when C3435T is mutated with a mutation from either exon 12 or exon 21 (or if all three mutations occur at the same time creating a haplotype), the inhibitors are less likely to weaken the function of MDR1. Multiple silent mutated genes tend to be more resistant against these inhibitors. Looking at the molecular level, the reason why C3435T in exon 26 of MDR 1 gene is not silent is because of the pace at which the amino acids are being translated to proteins. mRNA's secondary structures can fold which means different codons correspond to different folding's of the mRNA. For example, when exon 26 changes ATC to ATT both codons produce the same amino acid but ATC is seen more often than the mutation codon. As a consequence, the amount of time it takes for the ribosome to produce its protein confirmation is changed. This leads to a protein structure different from the usual shape of the protein which leads to different functions of the protein. Other reasons behind MDR1's "silent mutation" occurs in messenger RNA. In mRNA, codons also work as exon splicing enhancers. Codons decide when to cut out introns based on the codon it is reading in mRNA. The mutated codons have a higher risk of making a mistake when splicing introns out of the mRNA sequence leading to the wrong exons being produced. Therefore, making a change to the mature messenger RNA. Mutations in the Multi-Drug Resistance Gene 1 show how silent mutations can have an effect on the outcome of the phenotype.
Sources: en.wikipedia.org
The vagrant population of the Bowery declined after the 1970s, in part because of the city's effort to disperse it. Since the 1990s the entire Lower East Side has been reviving, and gentrification has contributed to ongoing change along the Bowery. In particular, the number of high-rise condominiums is growing. In 2007, the SANAA-designed facility for the New Museum of Contemporary Art opened between Stanton and Prince Street. In 2008, AvalonBay Communities opened Avalon Bowery Place, its first luxury apartment complex on the Bowery; the structure includes a Whole Foods Market. Avalon Bowery Place was quickly followed with the development of Avalon Bowery Place II. The new development has not come without social costs. Michael Dominic's 2001 documentary Sunshine Hotel followed the lives of residents of one of the few remaining flophouses. Construction on the Wyndham Garden Hotel at 93 Bowery in the late Aughts destabilized neighboring building 128 Hester Street (owned by the same man, William Su), and 60 tenants were thrown out of the building with the help of the Department of Buildings. At least 75 tenants were displaced from 83 to 85 Bowery in January 2018 in frigid temperatures due to long-overdue repairs that needed to be made. Tenants accused the landlord of using this displacement to start renovating the buildings into a hotel, and they went on a hunger strike. The Bowery from Houston to Delancey Street still serves as New York's principal market for restaurant equipment and from Delancey to Grand for lamps.
Acid guanidinium thiocyanate-phenol-chloroform extraction (abbreviated AGPC) is a liquid–liquid extraction technique in biochemistry and molecular biology. It is widely used for isolating RNA (as well as DNA and protein in some cases). This method may take longer than a column-based system such as the silica-based purification, but has higher purity and the advantage of high recovery of RNA. Furthermore, an RNA column is typically unsuitable for purification of short (<200 nucleotides) RNA species, such as siRNA, miRNA and tRNA. It was originally devised by Piotr Chomczynski and Nicoletta Sacchi, who published their protocol in 1987. The reagent is sold by Sigma-Aldrich by the name TRI Reagent; by Invitrogen under the name TRIzol; by Bioline as Trisure; and by Tel-Test as STAT-60.
=== Zeolites === Zeolites are natural or synthetic crystalline aluminosilicates, which have a repeating pore network and release water at high temperature. Zeolites are polar in nature. They are manufactured by hydrothermal synthesis of sodium aluminosilicate or another silica source in an autoclave followed by ion exchange with certain cations (Na+, Li+, Ca2+, K+, NH4+). The channel diameter of zeolite cages usually ranges from 2 to 9 Å. The ion exchange process is followed by drying of the crystals, which can be pelletized with a binder to form macroporous pellets. Zeolites are applied in drying of process air, CO2 removal from natural gas, CO removal from reforming gas, air separation, catalytic cracking, and catalytic synthesis and reforming. Non-polar (siliceous) zeolites are synthesized from aluminum-free silica sources or by dealumination of aluminum-containing zeolites. The dealumination process is done by treating the zeolite with steam at elevated temperatures, typically greater than 500 °C (930 °F). This high-temperature heat treatment breaks the aluminum-oxygen bonds and the aluminum atom is expelled from the zeolite framework.
=== 13 April === The Ukrainian Defence Ministry confirmed that Russian forces had reached the northern outskirts of Bohdanivka, ten kilometers from Chasiv Yar. Russia claimed to have taken Pervomaiske, 11 kilometers west of Avdiivka. Three people were killed in separate Russian attacks in Donetsk Oblast, while two people were killed in Kharkiv Oblast. One person was killed in a Russian attack on a car carrying humanitarian aid in Chernihiv Oblast. The Russian-installed head of Luhansk Oblast claimed that three people were injured in a Ukrainian missile attack on a factory in Luhansk city. Ukrainian officials claimed to have destroyed a major Russian headquarters using Storm Shadow missiles. Russian media later reported that Colonel Pavel Kropotov, commander of the 59th Guards Communications Brigade, was killed in the attack. The SBU announced that it had thwarted an assassination attempt against Kherson Oblast Governor Oleksandr Prokudin, adding that it had arrested a suspect who tried to launch a drone at his car. The IAEA reported that the Zaporizhzhia Nuclear Power Plant had been placed in a state of cold shutdown for the first time since October 2022. Germany announced that it would deliver another Patriot battery and additional missiles to Ukraine.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.